Welcome to our dedicated page for IMGO news (Ticker: IMGO), a resource for investors and traders seeking the latest updates and insights on IMGO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IMGO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IMGO's position in the market.
Imago BioSciences (Nasdaq: IMGO) reported financial results for the year ending December 31, 2021. The company highlighted positive interim Phase 2 data for bomedemstat in essential thrombocythemia (ET) and myelofibrosis (MF) presented at the ASH 2021 meeting. With cash reserves of $217.4 million, Imago plans to initiate two new clinical studies in 2022 and prepare for a registrational study for ET. However, the net loss for 2021 increased to $42.3 million from $17.8 million in 2020, indicating continued financial challenges.
Imago BioSciences (Nasdaq: IMGO) announced the appointment of Michael Arenberg as Chief Operating and Business Officer, effective March 23, 2022. With over 25 years in the biopharmaceutical industry, Arenberg previously served as CFO at DURECT Corporation. He will oversee strategic operations and business development as the company progresses its lead drug, bomedemstat, into Phase 3 trials. Additionally, Laura G. Eichorn has been confirmed as Chief Financial Officer, bringing her extensive operational experience to the role.
Imago BioSciences announced that CEO Hugh Y. Rienhoff, Jr., M.D. will participate in the Cowen 42nd Annual Health Care Conference from March 7-9, 2022. Dr. Rienhoff is scheduled for a discussion on Leukemias and Myeloproliferative Neoplasms on March 7 at 10:30 a.m. ET. The event will be available via live webcast on the company's website, with a replay accessible for 30 days post-event. Imago, focused on treating myeloproliferative neoplasms, is advancing its lead candidate, Bomedemstat, in Phase 2 trials.
Imago BioSciences (Nasdaq: IMGO) announced that CEO Hugh Y. Rienhoff, Jr., M.D., will participate in a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 10, 2022, at 10:30 a.m. PT / 1:30 p.m. ET. The live audio webcast can be accessed via the Investor Relations section of the company's website, with a replay available for 90 days post-event.
Imago is focused on developing novel therapies for myeloproliferative neoplasms (MPNs), with their lead product, Bomedemstat, currently in Phase 2 trials.
Imago BioSciences (NASDAQ: IMGO) presented encouraging findings from its Phase 2 clinical study of bomedemstat for treating essential thrombocythemia (ET) at the 63rd American Society of Hematology meeting.
Key results as of November 1, 2021, include:
- 100% of patients experienced platelet count normalization.
- 90% achieved a platelet count below 400 x 109/L without thromboembolic events.
- 71% reported a decrease in Total Symptom Score at 24 weeks.
The treatment was well-tolerated, with the company advancing toward a registrational trial.
Imago BioSciences presented positive data from a Phase 2 clinical study of bomedemstat for treating advanced myelofibrosis (MF) at the 63rd American Society of Hematology Annual Meeting. The trial, which fully enrolled 89 patients by May 2021, showed that 74% of patients experienced a reduction in Total Symptom Score (TSS) after 24 weeks. Additionally, 75% of patients had spleen volume reductions and 89% had stable or improved hemoglobin levels at 12 weeks. Bomedemstat was well-tolerated, with common side effects being mild.
Imago BioSciences is set to host a virtual investor event on December 12, 2021, at 11:00 a.m. ET. This follows their presentations at the 63rd American Society of Hematology (ASH) annual meeting. Interested individuals can join by dialing in or through a webcast on their website, available for 90 days post-event. The company will present two studies on their drug Bomedemstat (IMG-7289), targeting advanced myelofibrosis and essential thrombocythemia, with presentations scheduled for December 11 and 12.
Imago BioSciences, Inc. (Nasdaq: IMGO) announced the appointment of Laurie Keating to its Board of Directors on November 17, 2021. With over 40 years in the biopharmaceutical sector, Keating previously held roles at Alnylam Pharmaceuticals and Millennium Pharmaceuticals. CEO Hugh Young Rienhoff expressed enthusiasm for Keating's expertise, vital for advancing the company’s lead product, bomedemstat, a novel LSD1 inhibitor targeting myeloproliferative neoplasms. This appointment follows Imago's successful IPO in July, indicating strategic growth opportunities as the company progresses through regulatory processes.
Imago BioSciences, a clinical-stage biopharmaceutical firm, announced that CEO Hugh Y. Rienhoff, Jr., M.D. will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 10:40 a.m. ET. The presentation will be accessible via a live audio webcast on the company's website, with a replay available for 90 days afterward.
The company focuses on developing treatments for myeloproliferative neoplasms (MPNs), with Bomedemstat as its lead candidate, targeting lysine-specific demethylase 1 (LSD1). Bomedemstat has received several designations from the FDA and EMA.
Imago BioSciences (Nasdaq: IMGO) reported its Q3 2021 financial results, highlighting a cash position of $230.4 million and a net loss of $11.7 million, an increase from $4.3 million in Q3 2020. The company has accelerated its pipeline, completing enrollment in the Phase 2 trial of bomedemstat for myelofibrosis and announcing two oral presentations at the upcoming ASH meeting. The inclusion in the Russell 2000 Index and the Orphan Drug Designation for bomedemstat in essential thrombocythemia from the EMA further bolster its market presence.
FAQ
What is the market cap of IMGO (IMGO)?
